Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond

20251 citationsJournal Articlegold Open Access

Authors

Zein Alabdin Hannouneh · Al Andalus University

C. Elena Cervantes · Johns Hopkins University

Mohamad Hanouneh · Johns Hopkins University

Mohamed G. Atta · Johns Hopkins University

Abstract

SGLT2is play a crucial role in the management of DKD and HF by addressing multiple pathogenic pathways. Currently, SGLT2is are included in clinical guidelines for DKD and HF management, and their benefits extend to nondiabetic populations. Further research is needed to explore SGLT2is' multifaceted mechanisms and potential applications across diverse patient populations and different disease etiologies.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

Publication Details

Published in: Glomerular Diseases

Volume 5, Issue 1, pp. 119-132

DOI: 10.1159/000543685

Field-Weighted Citation Impact: 1.31

Command Palette

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond

Authors

Abstract

Topics & Keywords

Publication Details